Dashboard
Manage Tickers

RVMD


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

wedbush-maintains-outperform-on-revolution-medicines-raises-price-target-to-80
Wedbush Maintains Outperform on Revolution...
11/06/2025 13:37:28

Wedbush analyst Robert Driscoll maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target f...

needham-maintains-buy-on-revolution-medicines-raises-price-target-to-72
Needham Maintains Buy on Revolution Medici...
11/06/2025 13:19:33

Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $66 to $72.

hc-wainwright--co-maintains-buy-on-revolution-medicines-raises-price-target-to-73
HC Wainwright & Co. Maintains Buy on Revol...
11/06/2025 12:54:27

HC Wainwright & Co. analyst Robert Burns maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price ta...

revolution-medicines-q3-eps-161-misses-138-estimate
Revolution Medicines Q3 EPS $(1.61) Misses...
11/05/2025 21:04:11

stocks-rebound-eli-lilly-jumps-to-14-month-highs-whats-moving-markets-wednesday
Stocks Rebound, Eli Lilly Jumps To 14-Mont...
11/05/2025 18:23:55

Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid soli...

earnings-scheduled-for-november-5-2025
Earnings Scheduled For November 5, 2025
11/05/2025 11:12:12

rbc-capital-initiates-coverage-on-revolution-medicines-with-outperform-rating-announces-price-target-of-77
RBC Capital Initiates Coverage On Revoluti...
11/03/2025 14:20:20

RBC Capital analyst Leonid Timashev initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Outperform rating and an...

revolution-medicines-announces-fda-orphan-drug-designation-for-rason-multi-selective-inhibitor-daraxonrasib
Revolution Medicines' Announces FDA Orphan...
10/27/2025 12:16:22

tango-therapeutics-touts-encouraging-data-from-early-stage-cancer-trial-raises-capital-to-fund-advancement
Tango Therapeutics Touts Encouraging Data ...
10/23/2025 15:17:16

Tango Therapeutics Inc. (NASDAQ:TNGX) revealed data from its ongoing Phase 1/2 study of vopimetostat (TNG462) in patients with ...

revolution-medicines-reports-42-objective-response-rate-for-elironrasib-in-heavily-pretreated-kras-g12c-nsclc-patients-co-to-highlight-data-at-aacr-nci-eortc-symposium-october-23-25-2025
Revolution Medicines Reports 42% Objective...
10/22/2025 16:16:24

Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients wit...

mizuho-initiates-coverage-on-revolution-medicines-with-outperform-rating-announces-price-target-of-90
Mizuho Initiates Coverage On Revolution Me...
10/21/2025 12:47:09

Mizuho analyst Joseph Catanzaro initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Outperform rating and announ...

raymond-james-maintains-strong-buy-on-revolution-medicines-raises-price-target-to-76
Raymond James Maintains Strong Buy on Revo...
10/17/2025 16:34:01

Raymond James analyst Sean McCutcheon maintains Revolution Medicines (NASDAQ:RVMD) with a Strong Buy and raises the price ta...

revolution-medicines-disc-medicine-american-express-and-other-big-stocks-moving-higher-on-friday
Revolution Medicines, Disc Medicine, Ameri...
10/17/2025 16:02:18

fda-unveils-first-experimental-drugs-under-fast-track-voucher-plan-to-cut-drug-review-times
FDA Unveils First Experimental Drugs Under...
10/17/2025 14:03:18

The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, a...

wedbush-reiterates-outperform-on-revolution-medicines-maintains-77-price-target
Wedbush Reiterates Outperform on Revolutio...
10/17/2025 12:26:34

Wedbush analyst Robert Driscoll reiterates Revolution Medicines (NASDAQ:RVMD) with a Outperform and maintains $77 price target.

no-need-to-sell-martin-marietta-materials-cramer-says-its-just-a-great-long-term-hold
'No Need To Sell' Martin Marietta Material...
10/17/2025 11:46:17

Wells Fargo's Timna Tanners initiated coverage on Martin Marietta Materials with an Equal-Weight rating and announced a pri...

Core News & Articles
FDA Awards First-Ever National Priority Vo...
10/16/2025 21:27:26

https://www.fda.gov/news-events/press-announcements/fda-awards-first-ever-national-priority-vouchers-nine-sponsors

stifel-reinstates-buy-on-revolution-medicines-announces-85-price-target
Stifel Reinstates Buy on Revolution Medici...
10/16/2025 13:46:45

Stifel analyst Laura Prendergast reinstates Revolution Medicines (NASDAQ:RVMD) with a Buy and announces $85 price target.

goldman-sachs-maintains-buy-on-revolution-medicines-raises-price-target-to-73
Goldman Sachs Maintains Buy on Revolution ...
09/12/2025 17:07:29

Goldman Sachs analyst Andrea Newkirk maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target fro...

raymond-james-assumes-revolution-medicines-at-strong-buy-announces-price-target-of-72
Raymond James Assumes Revolution Medicines...
09/12/2025 12:13:02

Raymond James analyst Sean McCutcheon assumes Revolution Medicines (NASDAQ:RVMD) with a Strong Buy rating and announces Pric...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION